Fully human phage library
Fully human monoclonal antibodies can be obtained through rapid screening. At present, Weilizhibo has a number of monoclonal or double antibody components screened from fully human phage display libraries. These projects have entered or are about to enter the clinical development stage.
Humanization of Mouse Hybridoma Antibody
For more complex targets such as GPCR or targets that require special functions, mouse hybridoma technology is used to ensure the diversity of candidate molecules, and the final candidate molecules (or antibodies) are obtained through mature humanization technology.
single domain antibody
This technology is suitable for screening relatively stable and high-yield single domain antibodies.Single-domain antibodies have smaller molecular weight and better stability than traditional antibodies, and can recognize epitopes that traditional antibodies cannot.And it has better penetration and accessibility to tumor tissue and microenvironment.
The CD3 engager of Weilizhibo has a variety of designs for different tumor targets, including the combination of TAA targets with different expression levels, anti-CD3 activity regulation and tumor-directed activation, different price positions and spatial structures, so as to effectively Get a better balance between sex and security.At present, several CD3 double antibodies targeting solid tumors and hematological tumors have entered the preclinical development stage, and have shown strong anti-tumor effects and good safety in preclinical drug efficacy models and toxicology experiments .
Bifunctional Fusion Protein/Double Multispecific Antibody
The combination of different target monoclonal antibodies and fusion proteins or the combination of monoclonal antibodies and monoclonal antibodies forms a bifunctional effect or reduces the toxic side effects of the original monoclonal antibodies through better tumor targeting.Based on antibody engineering technology, Weilizhibo has established the company's unique 'MabFusion platform', a common light chain antibody platform, etc., which can be used for various symmetric bifunctional fusion proteins/bispecific antibodies and asymmetric bi/multiple antibodies. Development of specific antibodies.
The 4-1BB engager platform developed by Weilizhibo uses antibody engineering technology to balance the affinity of TAA targets and 4-1BB, and uses the combination of TAA targets to cross-link and activate 4-1BB receptors, so that the 4-1BB target functions of maximization.In preclinical models, it has been shown to promote the activation and proliferation of effector T cells, tend to tumor infiltration, inhibit Treg cells, reverse the various anti-tumor effects of the immune system in the tumor microenvironment, and avoid the possible liver damage caused by 4-1BB monoclonal antibody toxicity.At present, the project designed based on 4-1BB engager has been clinically verified for its safety and effectiveness.